ECOR

electroCore, Inc.

Nasdaq · Electromedical & Electrotherapeutic Apparatus · Inc. DE · CIK 0001560258
$9.64 +10.55% $80.0M
Insider Selling Cluster (2 insiders)
Vol
Market Cap$80.0M
Cap SizeMicro Cap
Inst. Holders6 funds
Inst. Value$1.4M
Inst. Activity1 buys / 1 sells
Insider Activity1B / 3S
Insider Net $-$116.4K
SEC Reports5
Press Releases3
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0001560258·Prev Close $8.72

Recent Activity

Jun 2, 2026 other
electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
<p>ROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracke
May 28, 2026 Insider
Lev Joshua S. sold 6,667 shares
CFO and Interim President @ $9.00 ($60.0K)
May 27, 2026 SEC
Director Thomas M. Patton filed a Form 144 indicating intent to sell 85,000 shares of electroCore (ECOR) valued at appro
144 — Impact 2/10
May 22, 2026 Insider
Lev Joshua S. sold 3,000 shares
CFO and Interim President @ $6.50 ($19.5K)
May 21, 2026 Insider
Errico Thomas J. bought 9,992 shares
Director @ $5.99 ($59.9K)
May 14, 2026 SEC
Director Daniel S. Goldberger filed a Form 144 to sell 45,000 shares of electroCore common stock, valued at approximatel
144 — Impact 2/10
May 5, 2026 SEC
Insider Daniel S. Goldberger (likely an officer/director) filed a Form 144 to sell 25,000 shares of ECOR, valued at appr
144 — Impact 4/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
54,486 shares ($244.4K)

Price Targets

Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$19.17 (Jan 2026)
Current $9.52 Low $12.00 Median $19.85 High $26.00 5 analysts
$12.00 $26.00

Analyst Ratings

Historical distribution91% buy · 11 analysts · last covering-analyst action Jan 2026
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Jan 26, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.41 ▼ -13.1% $-0.50 — $-0.31 6% YoY 5
Next Q $-0.29 ▲ +3.1% $-0.36 — $-0.23 28% YoY 5
Current FY $-1.50 ▼ -4.0% $-1.61 — $-1.43 9% YoY 5
Next FY $-0.43 ▲ +25.4% $-0.87 — $0.35 71% YoY 4

Top Institutional Holders

FundValueMove
VANGUARD GROUP INC$1.1MADD
RENAISSANCE TECHNOLOGIES LLC$244.4KTRIM
TWO SIGMA INVESTMENTS, LP$87.1KNEW
MORGAN STANLEY$18.8KDOUBLED
WELLS FARGO & COMPANY/MN$1.4K

Recent Insider Trades

DateInsiderTypeValue
May 28, 2026Lev JoshuaSELL$60.0K
May 22, 2026Lev JoshuaSELL$19.5K
May 21, 2026Errico ThomasBUY$59.9K
May 20, 2026Errico ThomasL$47.84
Apr 13, 2026Fox MichaelA$0.00
6 institutional holders with $1.4M total value (321,369 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1VANGUARD GROUP INC242,943$1.1M75.6%ADD +37.5%
2RENAISSANCE TECHNOLOGIES LLC54,486$244.4K17.0%TRIM -45.7%
3TWO SIGMA INVESTMENTS, LP19,421$87.1K6.0%NEW
4MORGAN STANLEY4,202$18.8K1.3%DOUBLED +194.9%
5WELLS FARGO & COMPANY/MN311$1.4K0.1%
6BANK OF AMERICA CORP /DE/6$27.000.0%NEAR_EXIT -94.4%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
RENAISSANCE TECHNOLOGIES LLCTRIM100,28654,486-45.7%$244.4K2025-Q4
MORGAN STANLEYDOUBLED1,4254,202+194.9%$18.8K2025-Q4
RENAISSANCE TECHNOLOGIES LLCTRIM180,686100,286-44.5%$496.4K2025-Q3
MORGAN STANLEYNEAR_EXIT18,4761,425-92.3%$7.1K2025-Q3
BANK OF AMERICA CORP /DE/NEAR_EXIT1076-94.4%$30.002025-Q3
TWO SIGMA INVESTMENTS, LPNEW20,372$107.6K2025-Q2
UBS Group AGADD5,4718,978+64.1%$47.4K2025-Q2
BANK OF AMERICA CORP /DE/DOUBLED47107+127.7%$565.002025-Q2
VANGUARD GROUP INCADD168,924232,333+37.5%$1.6M2025-Q1
RENAISSANCE TECHNOLOGIES LLCADD131,786178,425+35.4%$1.2M2025-Q1
UBS Group AGDOUBLED7935,471+589.9%$36.6K2025-Q1
RENAISSANCE TECHNOLOGIES LLCADD72,986131,786+80.6%$2.1M2024-Q4
MORGAN STANLEYDOUBLED17415,441+8774.1%$250.3K2024-Q4
UBS Group AGTRIM1,692793-53.1%$12.9K2024-Q4
MORGAN STANLEYDOUBLED1174+17300.0%$1.3K2024-Q3
4 unique insiders with 4 transactions. Net insider value: -$116.4K ($59.9K bought, $176.3K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 28, 2026Lev Joshua S.CFO and Interim PresidentSELL6,667$9.00$60.0K
May 22, 2026Lev Joshua S.CFO and Interim PresidentSELL3,000$6.50$19.5K
May 21, 2026Errico Thomas J.DirectorBUY9,992$5.99$59.9K
May 20, 2026Errico Thomas J.DirectorL8$5.98$47.84
Apr 13, 2026Fox MichaelChief Operating OfficerA70,000$0.00$0.00
Apr 10, 2026Goldberger Daniel SSELL16,072$6.02$96.8K
Apr 1, 2026Lev Joshua S.CFO and Interim PresidentA45,000$0.00$0.00
Mar 19, 2026Errico Thomas J.DirectorX22,803$0.00$0.00
Mar 19, 2026Errico Thomas J.DirectorX22,803$4.35$99.2K
Historical analyst distribution (last covering-analyst action Jan 2026): 91% buy across 11 analysts — 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$19.17 mean target (Jan 2026)
$12.00 Low $26.00 High
MetricValue
Current Price$9.52
Target Low$12.00
Target Mean$19.17
Target Median$19.85
Target High$26.00
# Analysts5
Recommendation— (no recent coverage)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$-0.41 $-0.50 $-0.31 5.9% -13.1% 1↑ 4↓ $0.0B 30.8% 5
Next Q
2026-09-30
$-0.29 $-0.36 $-0.23 28.5% +3.1% 1↑ 2↓ $0.0B 24.9% 5
Current FY
2026-12-31
$-1.50 $-1.61 $-1.43 9.1% -4.0% 1↑ 3↓ $0.0B 30.9% 5
Next FY
2027-12-31
$-0.43 $-0.87 $0.35 71.0% +25.4% 1↑ 2↓ $0.1B 29.3% 4

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.414
7d ago$-0.412-0.002
30d ago$-0.366-0.048
60d ago$-0.370-0.044
90d ago$-0.360-0.054
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jan 26, 2026 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263710091%
May 1, 20263710091%
Apr 1, 20263710091%
Mar 1, 20263710091%
Feb 1, 20263710091%
Jan 1, 20263710091%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 2, 2026
other
electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
<p>ROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=08MrtQLPsWyilQqy4g1aHTo_2bhFwlm1YvDRSZ07J86
May 9, 2026
other
electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
<p>ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company
May 5, 2026
earnings_calendar
ECOR Q1 2026 Earnings Scheduled — 2026-05-05
Apr 29, 2026
earnings
electroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026
<p>ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness compa
Apr 28, 2026
other
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
<p>ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness compa
Apr 23, 2026
other
electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation
<p align="justify">ROCKAWAY, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine an
Apr 1, 2026
fda
electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD
<p>ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness compa
Mar 19, 2026
earnings
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
<p align="center"><em>Record f</em><em>ull year 2025 net sales of {{SSR_CONTENT}}lt;/em><em>32.0</em><em>, an increase of 27% over $25.2 million for the full year 202
Mar 10, 2026
earnings
electroCore to Participate at the 38th Annual Roth Conference
<p>ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced tod
Mar 10, 2026
earnings_calendar
ECOR Q4 2025 Earnings After Market Close — 2026-03-10